Treatment of gummy smile using botulinum toxin by 紐낆뼇�샇
  
저작자표시-비영리-변경금지 2.0 대한민국 
이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게 
l 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.  
다음과 같은 조건을 따라야 합니다: 
l 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건
을 명확하게 나타내어야 합니다.  
l 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.  
저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다. 
이것은 이용허락규약(Legal Code)을 이해하기 쉽게 요약한 것입니다.  
Disclaimer  
  
  
저작자표시. 귀하는 원저작자를 표시하여야 합니다. 
비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다. 
변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다. 
Treatment of gummy smile using
botulinum toxin
Yang Ho Myung
The Graduate School
Yonsei University
Department of Dentistry
Treatment of gummy smile using
botulinum toxin
Directed by Professor Seong Taek Kim, D.D.S., Ph.D.
A Master’s thesis
Submitted to the Department of Dentistry
and the Graduate School of Yonsei University
in partial fulfillment of the requirements for the
degree of Master of Dental Science
Yang Ho Myung
December 2015

감사의 글
설레임과 두려움을 가지고 시작했던 석사학위 과정, 이제 비로소
석사학위 모든 과정을 마치고 지난 시간을 되돌아 봅니다. 작지만 수많은
노력이 모여 한편의 논문이 만들어 지는 것을 보면서, 한편의 논문을 위해
얼마나 많은 분들의 도움이 필요하며, 얼마나 많은 노력이 필요한지를
깨닫게 되었습니다.
무엇보다도 부족한 저를 위해 많은 가르침을 주시고 이끌어 주신 김성택
지도 교수님께 깊은 감사를 드립니다. 지도 학생으로서 마땅히 해야 할
도리를 다 하지 못한 것 같아 죄송한 마음 이루 다 말할 수 없습니다.
교수님의 격려와 지도 덕분에 무사히 석사학위 과정을 마칠 수 있었습니다.
또한 심사 과정에서 아낌 없는 조언과 격려를 해 주신 정의원 교수님과
정주령 교수님께도 진심으로 감사 드립니다.
그리고 언제나 믿어주고 적극 지원해주는 나의 동료이자 든든한 후원자인
사랑하는 아내 윤혜림,아빠의 빈자리가 있었지만 착하고 건강하게 무럭무럭
자라주는 나경, 용희 너무너무 감사합니다. 저를 낳아 주신 부모님 정말
감사합니다.
지금까지 제 옆에서 있어 주신 모든 분들께 사랑과 감사의 마음을 보내며
이 글을 마칩니다.
2015 년 12 월  
명양호 드림
iTABLE OF CONTENTS
TABLE OF CONTENTS····························································· i
LIST OF FIGURE AND TABLES ··············································· ii
ABSTRACT············································································ iii
I. INTRODUCTION··································································· 1
II. SUBJECTS AND METHOD ··················································· 3
III. RESULTS ·········································································· 5
IV. DISCUSSION···································································· 13
V. CONCLUSION···································································· 22
REFERENCES ······································································· 23
ABSTRACT (in Korean)························································· 26
ii
LIST OF FIGURE
Figure 1. Stepwise approach to select the included literature ······ 4
Figure 2. Main muscle involved in gingival exposure ··················13
LIST OF TABLES
Table 1. Summary of composition of patient in the treatment of
excessive gingival display············································ 7
Table 2. Summary of measuring method in the treatment of
excessive gingival display ··········································· 8
Table 3. Summary of BoNT in the treatment of excessive gingival
display ······································································· 9
Table 4. Summary of BoNT injection technique in the treatment of
excessive display·······················································10             
Table 5. Summary of outcomes in the treatment of excessive
gingival display ························································· 11
iii
Abstract
Treatment of gummy smile using botulinum toxin
Yang Ho Myung
Department of Dentistry
The Graduate School, Yonsei University
(Directed by Professor Seong Taek Kim, D.D.S., Ph.D.)
Excessive gingival exposure refers to gingival exposure of more than 2mm 
when smiling and it is considered as non-aesthetical. Causes of excessive 
gingival exposure onset include delayed eruption of tooth, vertical maxillary 
excess, hypermobile upper lip, and short upper lip. Either prosthodontic, 
corrective, or surgical treatment can be used depending on the cause of its 
onset. Recently, the treatment method of excessive gingival exposure using 
botulinum toxin (BoNT) was introduced as non-surgical method. Since 
treatment method is yet to be standardized, there is controversy over the 
treatment method or effect. 
Accordingly, the purpose of this study is to examine the role of BoNT as the 
treatment method for excessive gingival exposure and research guidelines for 
excessive gingival exposure research using BoNT in the future through 
literature review. 
iv
Online literature review was conducted via Pubmed, Scopus, and Web of 
science on April 1st, 2015. Keywords used for search were gummy smile, 
gingival exposure, or combination of gingival display with either botox, 
botulinum, onabotulinumtoxinA, or abobotulinumtoxinA. Thirty three literatures 
were searched as a result and 10 articles were used in this study excluding the 
23 literatures that did not meet the inclusion criteria.
As a result of literature review, it was revealed that BoNT treatment for 
excessive gingival exposure is reversible and effective treatment and side 
effects followed by BoNT injection was minimal and temporary. Also, the 
satisfaction of patients toward the treatment is high and treatment effect lasts 
for at least 12 weeks. Since there are several limitations in this research, 
clinically significant result may be acquired when well designed randomized 
controlled trials are conducted in the future. 
                                                                                      
Keywords: gummy smile, excessive gingival exposure, botulinum
toxin(BoNT)
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The Graduate School, Yonsei University
(Directed by Professor Seong Taek Kim, D.D.S., Ph.D.)
I. INTRODUCTION
A person’s beautiful smile is probably the most pleasing and meaningful facial 
expression. Beautiful smile should be symmetric and display less than 2~3mm of 
the gum. Excessive gingival exposure, which is commonly described as “gummy 
smile”, is a frequent cause of patient’s dissatisfaction, and more spotlight has 
been shed upon it recently in the dental field. Gummy smile may result from 
delayed eruption, vertical maxillary excess (VME), hypermobile upper lip 
(HUL), or a short upper lip (Humayun et al., 2010). Various treatment 
modalities have been tried till date for the treatment of gummy smile. Delayed 
eruption is treated by esthetic crown lengthening (Rosenblatt and Simon, 2006).
In case of VME, gummy smile is often treated alone by orthognathic surgery or 
a multidisciplinary approach with either orthognathic surgery, orthodontic 
treatment, periodontal treatment, or restorative dentistry is required (Garber
2and Salama, 1996). In case of short upper lip, it can be treated by lip 
lengthening, which has also been performed in conjunction with rhinoplasty (De 
Souza Pinto, 2003; Harpreet et al., 2014).
In case of HUL, various treatment approaches have been used, with highly
variable outcomes. Botulinum toxin(BoNT) type A (Polo,2005; Mazzuco and
Hexsel, 2010), lip repositioning (Rubinstein and Kostianovsky, 1973; Rosenblatt
and Simon, 2006; Simon et al., 2007), detachment of lip muscle (Litton and 
Fournier, 1979) and lip repositioning combined with gingivectomy (Gabric et al., 
2014) are the reported treatment approaches. 
Spotlight has been shed upon BoNT injection among such various treatment 
methods of gummy smile because it is a simple, non-invasive, and reversible 
treatment with less side effects. Polo (2005) has introduced for the first time 
the method to inject BoNT to muscle around the lip. BoNT is produced by the 
anaerobic bacterium Clostridium botulinum. There are 8 different serotypes of 
BoNT. Type A is the most potent and the most commonly used clinically. BoNT
weakens skeletal muscles by cleaving the synaptosome-associated protein 
SNAP-25, thus blocking the release of acetylcholine from the motoneuron and 
enabling the repolarization of the postsynaptic terminal. As a result, the 
muscular contraction is blocked. 
Although gummy smile treatment method using BoNT has advantages of being 
safe, reliable, and reversible, it was introduced relatively recently thus there are 
limitations in that there is not many literatures and research methods and 
treatment methods of each research differ vastly. Since there is no standardized 
treatment method yet, there still is a controversy over the treatment method or 
effect. 
Accordingly, the purpose of this study is to provide a summary of treatment 
method and road map for studies on gummy smile treatment using BoNT in the 
future through literature review on gummy smile treatment using BoNT. 
3II. SUBJECTS AND METHOD
This review included all studies related to the treatment of gummy smile with 
BoNT injection until March 2015. Online literature review was conducted via 
Pubmed, Scopus, and Web of science on April 1st of 2015. Twelve keywords 
were used. Twelve keywords were combination of gummy smile OR gingival 
exposure OR gingival display AND botox OR botulinum OR onabotulinumtoxinA 
OR abobotulinumtoxinA. Thorough analysis was conducted for searched 
literatures. Exclusion criteria included the cases that do not concern gummy 
smile treatment, propose gummy smile treatment case reports, prescribe the 
BoNT, and cases that use treatment method other than BoNT treatment. 
The selected literatures were analyzed by the following items- gender and 
age of patients, measuring site  and measuring method of gummy smile,  product 
and preparation of botulinum toxin used in the treatment, target muscle and 
injection point used in the treatment, pre-treatment gingival exposure, post-
treatment gingival exposure, improvement percentage, satisfaction evaluation, 
short term adverse events, treatment longevity.
4Figure 1. Stepwise approach to select the included literature
5III. RESULTS
Thirty three papers were acquired as a result of online literature search via 
Pubmed, Scopus, and Web of science. Twenty three papers among them were 
excluded as it fell under the exclusion criteria. Four papers described other 
treatment methods (surgery or laser) for gummy smile and 19 papers were 
either irrelevant to gummy smile treatment, not specific to gummy smile 
treatment, and give no description on BoNT injection and its effect. Therefore, 
10 papers were used for this review.
Composition of patients
Number of subjects who received BoNT injection treatment in 10 papers was 
131 in total. When disregarding the 4 papers which do not present either sex or 
age of the treatment subject, most of treatment subject was female with wide 
range of age distribution from 15-48. Eight papers have described the 
treatment subject selection criteria for BoNT injection treatment and 7 papers 
considered pure HUL patients as the subject excluding patients with VME and 
delayed passive eruption of teeth. One literature conducted treatment with 
patient which require surgical treatment as its subject (Table 1). 
Measurement of gummy smile
In regards to the measurement parts for quantity of gummy smile, it was 
mostly measured at the central incisor. It sometimes was measured at the 
canine teeth or the first premolar. As a method to measure the quantity of 
gummy smile, 7 literatures conducted indirect measurement with the use of 
photograph or video equipment and 1 literature conducted repetitive 
measurement by putting ruler directly to the face. Also, in order to acquire 
6maximal smile during the process of measuring the quantity of gummy smile, 2 
papers described that funny joke or statement was used and 1 paper described 
that it was measured upon the emergence of expression of eye such as squint 
(Table 2). 
Botulinum toxin
Nine studies used onabotulinumtoxinA (Botox, Allergan, Irvine, California) with 
concentration raging from 2U/0.1mL to 5U/0.1mL. One study used 
abobotolinumtoxinA (Dysport, Ipsen Biopharm Limited, Wrexham, United 
Kingdom) with a concentration of 25 U/0.1mL. The total dose of BoNT injected 
per side ranged from 1.95 to 6.25 U and from 2.5 to 7.5 U for 
onabotulinumtoxinA and abobotulinumtoxinA, respectively (Table 3).
Injection technique
There were 1 to 3 injection points per each side and levator labii superioris
alaque nasi (LLSAN) was presented to be muscle targeted by injection in 9 
papers excluding 1 paper which identified gummy smile as anterior, posterior, 
mixed and asymmetric. Other muscles targeted by injection are levator labii 
superioris (LLS), zygomaticus major (ZM), zygomaticus minor (Zmi), and 
depressor setpi nasi (DSN). In order to determine the location of injection, 3 
papers used electromyography, 5 used the distance from particular landmark, 
and 2 pinpointed the location by touching the contracted muscle during smile to 
ensure precise muscle location before injection (Table 4). 
Treatment outcomes
The degree of improvement in gingival exposure before and after the 
treatment observed to be varying from 60.1 to 98% in 6 papers. The evaluation 
on satisfaction after treatment was conducted in 4 papers and presented high 
7degree of satisfaction but short-term adverse events were proposed in 3 
papers. The treatment longevity was reported in Table 5. 
Table 1. Summary of composition of patient in the treatment of excessive gingival
display
Study
Number
of
patients
Gender ratio
(woman : man)
Age(range) Selection of patients
Polo, 2005 5 Women (16~23) Hyperfunctional upper lip
Kim et al., 2006 5 Women 29.8(27~36) None
Polo, 2008 30 (29:1) 24.4(15~41) Hyperfunctional upper lip
Hwang et al., 2009
1 Woman 25 Hyperfunctional upper lip
1 Woman 18 Asymmetric smile
Gracco and Tracey,
2010
3 Women None
Surgical treatment needed
patient
Mazzuco and
Hexsel, 2010
3 None None The patients had visited
dentists and reported not
having received any
indication for surgical
treatment and claimed they
were unwilling to undergo
such a treatment modality.
7 None None
3 None None
3 None None
Sucupira and
Abramovitz, 2012
52 None None None
Dinker et al., 2013 1 Woman 23 Hyperfunctional upper lip
Singh et al., 2014 3 Woman None Hyperfunctional upper lip
Suber et al., 2014 14 (13:1) 34y(23~48) Cuspid smile patient
Total 131
8Table 2. Summary of measuring method in the treatment of excessive gingival
display
Study
Measuring
method
Measuring site
Evaluation or
inducement of
maximum smile
Polo, 2005 Photograph Central incisor None
Kim et al., 2006 None None None
Polo, 2008
Photograph,
video
recording
Central incisor
Extremely funny
joke
Hwang et al.,
2009
None None None
Gracco and
Tracey, 2010
Video
recording
Central incisor None
Mazzuco and
Hexsel, 2010
Photograph
Anterior GS Central incisor
None
Posterior GS First premolar
Mixed GS Central incisor
Asymmetric GS First premolar
Sucupira and
Abramovitz,
2012
Photograph None None
Dinker et al.,
2013
Photograph Central incisor Expression of eye
Singh et al.,
2014
Photograph Central incisor None
Suber et al.,
2014
Standardized
measuring
tape
Right and Left central incisor,
Right and Left canine
Funny joke or
statement
GS, gummy smile
9Table 3. Summary of BoNT in the treatment of excessive gingival display
Study Product and preparation Units per side(U)
Polo, 2005
Botox(OnabotulinumtoxinA) 
2.5U/0.1ml
5~6.25U
Kim et al., 
2006
Botox(OnabotulinumtoxinA)
None
5U
Polo, 2008
Botox(OnabotulinumtoxinA) 
2.5U/0.1ml
5U
Hwang et al., 
2009
Botox(OnabotulinumtoxinA) 
5.0U/0.1ml
GS 3U
Asymmetric GS Unilateral injection
Gracco and 
Tracey, 2010
Botox(OnabotulinumtoxinA) 
2.5U/0.1ml
2.5U
Mazzuco and 
Hexsel, 2010
Dysport(AbobotulinumtoxinA) 
25U/0.1ml
Anterior GS 2.5 or 5U
Posterior GS 5 U
Mixed GS 6.25U or 7.5U
Asymmetric GS
5U onside and 2.5U 
on the other
Sucupira and 
Abramovitz, 
2012
Botox(OnabotulinumtoxinA) 
3.1U/0.1mL
1.95U
Dinker et al., 
2013
Botox(OnabotulinumtoxinA)
2.5U/0.1mml
2.5U 
Singh et al., 
2014
Botox(OnabotulinumtoxinA)
5U/0.1mL
3U 
Suber et al., 
2014
Botox(OnabotulinumtoxinA) 
2U/0.1ml
4~6U 
GS, gummy smile
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Table 4. Summary of BoNT injection technique in the treatment of excessive
gingival display
Study Target muscle
Injection 
point
Determination of injection point 
Polo, 2005 LLSAN, LLS, ZM, DSN 2 or 3point EMG
Kim et al., 2006 LLSAN, LLS 2point EMG
Polo, 2008 LLSAN, LLS, ZM 2point Manual*
Hwang et al., 
2009
LLSAN, LLS, ZM 1point Yonsei point*
Gracco and 
Tracey, 2010
LLSAN,LLS,ZM 1point
10mm lateral to and 5mm 
inferior to the nasal ala
Mazzuco and 
Hexsel, 2010
Anterior GS LLSAN 1point
1 cm lateral and below the 
nasal ala
Posterior GS ZM, Zmi 2point 2 injection point*
Mixed GS
LLSAN, 
ZM, Zmi
3point
Both anterior GS and posterior 
GS injection points 
Asymmetric GS ZM, Zmi 2point Posterior GS injection points  
Sucupira and 
Abramovitz, 2012
LLSAN 1point 3 to 5mm lateral to the nostril
Dinker et al., 2013 LLSAN, LLS, ZM 2point Manual*
Singh et al., 2014 LLSAN, DSN 2point EMG
Suber et al., 2014 LLSAN, LLS 3point 3 injection point *
GS, gummy smile; LLSAN, levator labii superioris alaque nasi; LLS, levator labii superioris; ZM,
zygomaticus major; Zmi, zygomaticus minor; DSN, depressor setpi nasi; Yonsei point *, 1cm lateral to
the ala horizontally and 3cm above the lip line vertically; EMG, electromyographic guidance; Manual*,
determined by muscle animation(smiling) and palpation on contraction; 2 injection point * : (1) nasolabial
fold, at the point of greatest lateral contraction during the smile (2) 2 cm lateral to the first point, at the
level of the tragus; 3 injection point * : (1) 2mm lateral to the alar-facial groove (2) 2mm lateral to the first
injection (3) 2mm inferior and between the first 2mm sites
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Table 5. Summary of outcomes in the treatment of excessive gingival display
Study
Pre- treatment gingival exposure
(mm)
Post- treatment
gingival exposure
(mm)
Improvement
percentage
(%)
Polo, 2005 4.2mm 0mm None
Kim et al., 2006 6.7mm 1.7mm 75% at 4(W)
Polo, 2008 5.2mm 0.09mm 98% at 2(W)
Hwang et al., 2009
GS 5mm 2mm None
Asymmetric GS 4mm Symmetric smile None
Gracco and Tracey,
2010
Case 1 None None None
Case 2 6mm 0mm None
Case 3 4.5mm 0mm None
Mazzuco and
Hexsel, 2010
Anterior GS None None
96% at
20~30 days
Posterior GS None None
61.1% at
20~30 days
Mixed gummy GS None None
90.1% at
20~30 days
Asymmetric GS None None
71.9% at
20~30 days
Sucupira and
Abramovitz, 2012
3.62mm 0.58mm 84% at 2(W)
Dinker et al., 2013
Posed 4~5mm None None
Unposed 8~10mm None None
Singh et al., 2014 4mm 0.8mm 80% at 2(W)
Suber et al., 2014
Central incisor 4.89mm 0.75mm
85% at 2(W)
Canine 4.25mm 0.74mm
GS, gummy smile; (W), weeks
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Table 5. (continued)
Study Satisfaction evaluation Short term adverse events
Treatment
longevity
(weeks)
Polo, 2005 None None 12~24
Kim et al., 2006 None None 16~24
Polo, 2008
Average patient satisfaction
was 4.66 on a 5-point scale.
A little discomfort * >24
Hwang et al.,
2009
GS None None 20
Asymmetric GS None None None
Gracco and
Tracey, 2010
None None None
Mazzuco and
Hexsel, 2010
Anterior GS None None 12~20
Posterior GS None None 12~20
Mixed GS None
One patient- slightly asymmetric
smile,
One patient- “sad smile”
12~20
Asymmetric GS None None 12~20
Sucupira and
Abramovitz, 2012
Average patient satisfaction
was 9.75 on a 10-point scale.
Average pain was 1.74 on a 10-
point scale.
>12
Dinker et al.,
2013
None None None
Singh et al., 2014
Based on VAS assessment, all
patients were pleased with
the treatment results.
None 24
Suber et al., 2014
Based on 5-point scale, 13 of
14 particiants were satisified
with their results.
None 12
GS, gummy smile; A little discomfort *, Eight subjects reported pain at injection sites and 4 subjects
reported twitching at the injection site. One subject experienced headache and 1 subject experienced
dizziness.
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IV. DISCUSSION
It is said that aesthetic appearance of a smile is created by harmony between
teeth, lip framework, and gingival scaffold (Garber and Salama, 1996). The lip
framework is determined by the activity of various facial muscles, such as LLS,
LLSAN, ZM/Zmi. Such muscle plays a role of lifting the upper lip and pulling it
toward side when smiling and it creates smile through interaction with depressor
septi nasi muscle, risorius, and orbicularis oris muscle (Figure 1). Although
beautiful smile can be created when there is adequate interaction between
muscles, excessive gingival display occurs when excessive muscle capacity is
applied to lift upper lip.
Figure 2. Main muscle involved in gingival exposure
   The method to improve gummy smile through muscle hyperactivity can largely
be divided into surgical and non-surgical method. Various methods have been
introduced since Rubinstein and Kostianovsky (1973) have introduced their
surgical method and as its limitation the discomfort and side effects followed by
the surgery, relapse, and others have been proposed (Ellenbogen, 1984). In
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regards to non-surgical method, Polo (2005) has introduced for the first time
the method to inject BoNT to muscle around the lip. It has many advantages
including less discomfort and side effects after the treatment and non-surgical
method.
Although gummy smile treatment method using BoNT has advantages of being
safe, reliable, and reversible, it was introduced relatively recently thus there are
limitations in that there is not many literatures and research methods and
treatment methods of each research differ vastly. Accordingly, the purpose of
this review is to summarize research methods and treatment methods applied in
each literature and provide roadmap for future studies.
Composition of patients
Age and gender
Looking into the treatment subject, most of treatment subject was women with
wide range of age distribution from 15 to 48 excluding 4 papers which do not
reveal sex or age of treatment subject. The fact that majority of gummy smile
treatment subject is women can be understood when considering the study by
Tian et al. (1984) which suggests that women are more interested in aesthetics
compared to men and high smile is more dominant in women while low smile is
more dominant in men. Also, the fact that treatment subject is young is
meaningful. Niamtu (2008) suggested that satisfaction of gummy smile patients
treated with BoNT was low and it was because the age of treatment subject was
relatively old ranging from 35 to 60. In case of young adult, there is an increase
in treatment satisfaction since they are more sensitive to aesthetics and have
more tolerance to discomfort that generates from the treatment. On the other
hand, in case of older people, there was an aggravation in discomfort and
decrease in treatment satisfaction because decrease in muscle tone accompanied
by aging process accelerated with the BoNT treatment. Therefore, it was
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determined that there is a necessity to make distinction of age in future BoNT
studies.
Smile pattern
Not only distinctions about patients’ age but also smile pattern is necessary to
acquire adequate treatment effect. Among searched papers, 1 paper has
considered the smile type and selected cuspid smile patient was selected as a
result (Suber et al. 2014). Rubin (1974) has classified the smile patterns into 3
including “Mona Lisa”, “canine smile”, “full denture smile”. A “Mona Lisa” smile is
dominated by the ZM muscle and depicted by sharply elevated corners. A
“canine smile” is characterized by an elevation over the medial portion of the
upper lip via a prominent levator labii superioris action. Last, a “full denture”
smile is dominated by all of the upper retractor muscles in addition to the lower
depressors, resulting in a smile that exposes all teeth. Kane (2003) observed
that dissatisfied study participants in his BoNT study tended to be patients with
a “Mona Lisa” or “full denture smile”. Injections of BoNT further depresses upper
lip elevation compared with the commissures, leading to a cartoonish smile in
patients with a “Mona Lisa smile” or results in a grimace for patients with a “full
denture smile”. Therefore, it is determined that consideration on patient smile
type in the future is necessary since understanding on smile type of patients can
also increase the success rate of treatment using BoNT.
Measurement of gummy smile
Maximal smiling
In regards to the measurement of excessive gingival exposure, one of the
criteria to determine treatment effect, the measurement method varied for each
researcher thus there was controversy in examining the treatment effect. The
16
acquisition of “maximum smile” or “unposed smile” before and after the treatment
is an important criteria to examine the treatment effect. Since the patients
receiving the treatment know that the goal of treatment is to show less gum,
they may not present maximum smiling for post-treatment smile photo either
intentionally or unintentionally different from that of pre-treatment. Therefore,
there is a possibility that the treatment effect may be distorted. Such fact can be
examined from the comment of Niamtu (2008) regarding the BoNT study by
Polo (2005). Therefore, additional effort is necessary to acquire maximum
smiling and such effort was presented in 3 among 10 papers. Two literature
described that the maximum smile of patients was promoted through funny joke
or statement and 1 literature suggested that there is an emergence of maximum
smile when there is an expression of eye such as squint. As it was mentioned by
Niamtu (2008), the only reliable means of controlling smile dynamics would be
to accurately stimulate the individual muscles with electrical current (before and
after the treatment) with needle electrodes; this would result in controlled,
precise, and repeatable contractions. Obviously, this would be a painful situation
and almost impossible to duplicate in an awake and conscious patient in the
upright position. Therefore, in order to secure the objectivity of gingival
exposure quantity before and after the treatment in future studies, study should
be conducted with the effort to induce maximum smile.
Measurement of gingival exposure
Method to measure the degree of gingival exposure is as important an item as
maximal smiling induction. Eight among 10 papers described about methods to
measure the degree of gingival exposure. Five papers measured the degree of
gingival exposure through photography, Polo (2008) used photography and
video together, and Gracco and Tracey (2008) took a video. Suber et al (2014)
conducted 4 repeated measurement with the use of standardized measuring tape
without taking photo and it was because the moment of maximal smile
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emergence cannot accurately be taken with a photo. As it was mentioned by
Suber et al (2014), it is difficult to capture maximal smile from single moment of
time. Therefore, maximal smile screenshots acquired from video can be used as
more objective data compared to photography. Also, the studies by Mazzuco and
Hexsel (2010) and Polo (2005), the effort was made to narrow down the error
between before and after treatment using computer program or reference point
to compensate the error that generates from photography at the same
environment. It would also be an item to be considered when conducting studies
in the future.
BoNT
Product and preparation 
Nine papers from this literature review used onabotulinumtoxinA (Botox,
Allergan, Irvine, California) and 1 paper used abobotulinumtoxinA (Dysport,
Ipsen Biopharm Limited, Wrexham, UK). Considering the fact that standard
conversion rate of abobotulinumtoxinA and onabotulinumtoxinA is 2.5 U:1 U in a
study by Karsai and Raulin (2009), the dose of BoNT in Mazzuco and Hexsel
(2010) using abobotulinumtoxinA of 2.5-7.5 U can be considered as comparable
with the dose of 9 other papers which used onabotulinumtoxinA of 1.95-6 U.
Since the BoNT of similar dose was used, onabotulinumtoxinA and
abobotulinumtoxinA presented similar improvement effect. However, since
abobotulinumtoxinA presents greater efficacy and longer duration of effect,
there is an increase in possibility of side effects (Simonetta et al., 2003). Also
considering the fact that onabotulinumtoxinA is spreading to relatively safe and
small area compared to abobotulinumtoxinA, it can be determined that
onabotulinumtoxinA is more adequate to be used for facial expression muscle
treatment. Therefore, comparative studies between onabotulinumtoxinA and
abobotulinumtoxinA would have significance in future studies.  
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Used dosage per side
Looking into the dose of BoNT presented in 10 literatures, it was observed to
vary from 1.95-6.25 U but low dose or high dose was both effective in the
treatment. Garcia and Fulton (1996) showed that low dose injection of BoNT per
muscle (2-5 IU) was as effective as higher doses. Kane (2003) treated
excessive gingival display through improvement of the nasolabial fold, targeting
the LLSAN with 5 U per side. The injection dose was 1 U initially; at 2 to 3
weeks’ follow-up, the subsequent dose was determined according to clinical
response. This is a good and cautious approach that helps to prevent undesirable
side effects related to excessive doses or excessive potency of the selected
dose for a specific patient. Polo (2013) advised that the dose and injection sites
of BoNT should be tailored to the severity of gingival display: 1 injection site
and 2 U per side when the gum exposure is inferior 4~5 mm, 1 injection site and
2.5U per side when the gingival exposure is 5~7mm, 2 injection sites and 2.5U
injection when it exceeds 7 mm. Therefore, in order to treat gummy smile, the
method to inject different amount based on the quantity of gummy smile rather
than injecting fixed amount is necessary. At the moment, the method to inject
small amount first and then inject some more through retouching when
necessary is determined to be more adequate as a safe approach method.
Injection technique
Target muscles
In 10 papers, LLSAN is consistently injected muscle. The LLSAN originates
from the frontal process of the maxilla and inserts into the upper lip and the skin
tissue or the ala of the nose (Fehrenbach and Herring, 2002). From the studies
by Sucupira and Abramovitz (2012) and Mazzuco and Hexsel (2010) which
injected BoNT to LLSAN muscle only, the improvement quantity of gummy
smile was 84% and 96%. From the study by Mazzuco and Hexsel (2010) which
injected BoNT in ZM and Zmi muscle excluding LLSAN, the improvement
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quantity of gummy smile was 61.1% and 71.9%. This entails that LLSAN is an
important target muscle in BoNT injection. As it was mentioned in the study by
Mazzuco and Hexsel (2010), however, the improvement in posterior gummy
smile maybe difficult with LLSAN injection only as it receives more influence
from zygomaticus muscles thus it is difficult to consider LLSAN as an essential
muscle in gummy smile treatment.
Injection point
In order to inject BoNT to muscles (LLS, ZM, Zmi, DSN) other than LLSAN,
number of points was diversified from 1 to 3 point in each paper. Increasing the
number of injection points does not seem to lead to an improved outcome.
Sucupira and Abramovitz (2012) reported the improvement quantity of 84% with
1 point injection and Polo (2008) reported the improvement quantity of 98%
with 2 point injection. Suber et al (2014) reported the improvement quantity of
85% by conducting 3 point injection. Of course such phenomenon may come
from the fact that there is a difference in the quantity of gummy smile before
treatment and number of samples between each paper. Therefore, it is
necessary to conduct studies on relation between the number of points and
improvement quantity of gummy smile in the future.
Determination of injection point
Method to locate injection point was observed differently in each paper. Three
papers used electromyography, 2 papers pinpointed the location by feeling the
contraction of muscle while smiling with the use of fingers and 5 papers used
the method to conduct injection to certain distance from particular landmark. In
order to pinpoint accurate location of muscle, it is of great assistance to use
electromyography (Pessa et al., 1998, Klein and Mantell, 1998) but the use of
electromyography has limitation that it brings about pain and inconvenience.
Considering the fact that BoNT spreads 1~2cm from the point, method to use
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landmark can be considered as effective. Relevant to such point, Hwang et al.
(2009) proposed “Yonsei point” which can deliver BoNT to LLSAN, LLS, and
Zmi with 1 point injection through cadaver study. This landmark was identified
as the center of a triangle formed by the convergence of the LLSAN, the LLS,
and the Zmi muscles and is located 1 cm lateral to the ala horizontally and 3 cm
above the lip line vertically in both men and women.
Treatment outcomes
Longevity
Looking into the treatment longevity, the most of studies reported the
treatment effect of 12 up to 20 weeks. Polo (2008) noted that the average
gingival show had still not returned to baseline values at 24 weeks post-
injection. Mazzuco and Hexsel (2010) demonstrated that there is prolonged
reduction of gingival exposure following several injections of BoNT. It is
determined that such phenomenon occurs due to reduction in muscle volume and
contraction capacity followed by temporary paralysis even if BoNT effect
disappears.
Short term adverse events
Although most of patients expressed satisfaction toward the treatment in
treatment result assessment, short-term discomfort was observed from some
patients. Although some patients expressed discomfort at the time of injection
insertion and some expressed headache and dizziness after the injection in the
study by Polo (2008), it was mostly a temporary symptom and recovery of
symptom was observed within several days. In the study by Mazzuco and
Hexsel (2010), slightly asymmetric smile and sad smile were observed and such
discomfort was improved with additional injection. Although such discomfort is
temporary phenomenon and it can easily be improved through retouching in
follow-up period, side effects that last for several months are observed from
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some patients (Carruthers and Carruthers, 2004; Niamtu 2008). Therefore,
Niamtu (2008) and Ahn et al. (2013) asserted that BoNT injection should be
conducted by highly experienced practitioners only.
There are several limitations to this review. Since BoNT treatment was
introduced relatively recently, there are limitations in that there are small
number of research papers and all of them had small sample sizes. Also, there
exists the difference in treatment method and treatment subject between
researchers thus comparison between each study is difficult. In addition, the
lack of a randomized controlled trial prevented us from performing a traditional
meta-analysis and limited our systematic review to a form of pooled analysis.
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V. CONCLUSION
The purpose of this study was to review the studies on treatment of gummy
smile using BoNT injection. For gummy smile treatment, BoNT injection is non-
surgical, reversible, and effective treatment method. As a result of literature
review, LLSAN muscle was revealed to be most important muscle in gummy
smile treatment and there are LLS, ZM, Zmi, and DSN as other important
muscles. Both low and high dose of BoNT presented gummy smile improvement
effect. Since high dose of botulinum injection could induce adverse effect, it is
adequate to take safe approach method where low dose is injected first and
inject some more as retouching when necessary. Also, it was revealed that the
side effects followed by BoNT injection is temporary and treatment effect lasts
for at least 12 weeks. Since this paper has some limitations, I believe that
clinically significant result could be acquired when future adequately designed
and randomized controlled trials are conducted.
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국문요약
보툴리눔 독소를 이용한 치은과다노출증의 치료
<지도 김 성 택 교수>
연세대학교 대학원 치의학과
명 양 호
미소시 2mm 이상 치은이 노출되는 치은과다노출증은 비심미적으로 인식된다.
치은과다노출증의 발생원인은 치아의 지연맹출, 상악골의 수직성장, 상순의 과운동성, 
짧은 상순에 의해 발생되는데, 발생 원인에 따라 보철적 치료, 교정적 치료, 수술적
치료를 이용할 수 있다.  
최근 비수술적 방법으로 보툴리눔독소를 이용한 치은 과다노출증의 치료법이
소개되었는데, 치료방법이 아직 표준화되지 않은 관계로, 치료 방법이나 치료 효과에
대한 논란의 여지가 있다. 이에 본 연구에서는 문헌고찰을 통하여, 치은과다노출증
치료방법으로서 보툴리눔독소의 역할과 향후 보툴리눔독소를 이용한 치은과다노출증의
연구시 연구지침을 알아보고자 하였다.
2015 년 4 월 1 일 기준으로 Pubmed, Scopus, Web of science 에서 온라인
문헌검색을 시행하였다. 검색에 사용한 키워드는 gummy smile 혹은 gingival exposure 
혹은 gingival display 와 botox 혹은 botulinum 혹은 onabotulinumtoxinA 혹은
abobotulinumtoxinA 의 조합으로 하였다.
문헌 검색결과 33 개의 문헌이 검색되었고, 이 중 기준에 맞지 않은 23 개의 문헌을
제외한 10 개의 논문을 이번 연구에 이용하였다.
문헌고찰 결과 치은과다노출증의 보툴리눔독소 치료법은 가역적이며 효과적인
치료방법이고, 보툴리눔독소 주입시 발생하는 부작용은 작고 일시적이며, 치료에 대한
환자의 만족도가 높고, 치료 효과는 최소 12 주 이상 지속됨을 알 수 있었다. 이 논문은
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몇몇 한계점을 가지고 있기 때문에 향후 잘 디자인 된 무작위 비교연구를 시행한다면,
임상적으로 의미 있는 결과를 얻을 수 있을 것으로 판단된다.
핵심되는 말: 과다치은 노출, 보툴리눔 독소
